N
LGND icon

Natixis’s Ligand Pharmaceuticals LGND Stock Holding History

Natixis’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-200
Closed -$21.4K – 1098
2024
Q4 		$21.4K Buy
+200
New +$22.6K ﹤0.01% 934
2021
Q2 		– Sell
-17,793
Closed -$1.69M – 906
2021
Q1 		$1.69M Buy
+17,793
New +$1.68M 0.01% 735
2019
Q3 		– Sell
-8,930
Closed -$636K – 876
2019
Q2 		$636K Buy
+8,930
New +$658K ﹤0.01% 582

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Natixis's LGND Position: Q1 2025 in Review

Natixis sold out of Ligand Pharmaceuticals (LGND) in Q1 2025, closing a stake of 200 shares — an estimated $21.4K sold.

Natixis first reported a position in LGND in Q2 2019 and held it in 3 quarters. The position peaked at $1.69M in Q1 2021. 262 funds tracked by Wall St. Rank hold LGND as of Q1 2025.

  • Natixis reported no remaining Ligand Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Natixis sold 200 Ligand Pharmaceuticals shares in Q1 2025, an estimated $21.4K.
  • Natixis first reported a position in Ligand Pharmaceuticals in Q2 2019 and held it in 3 quarters.
  • Natixis's Ligand Pharmaceuticals position peaked at $1.69M in Q1 2021.
  • 262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2025.

Based on Natixis's 13F filing for Q1 2025, filed 14 May 2025.